AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and rare disease portfolios. The company delivered approximately $52.6 billion in total revenue for 2025, supported by strong performance from key growth brands and expanding global demand.
The results reinforce AstraZeneca’s strategy of combining scientific depth within focused therapeutic areas with scalable global commercialization.
2025 Key Brand Sales Insights
Oncology — Primary Growth Engine
Tagrisso
- 2025 Sales: ~$6.4 billion
Tagrisso continues to lead in EGFR-mutated lung cancer across early and advanced settings.
Executive Insight:
Early-stage adoption and global guideline positioning sustain long-term oncology leadership while expanding total addressable patient populations.
Imfinzi
- 2025 Sales: ~$4.8 billion
Imfinzi maintains momentum across lung and other solid tumors.
Executive Insight:
Expansion into combination regimens strengthens AstraZeneca’s immuno-oncology footprint and deepens its role in standard-of-care pathways.
Enhertu (in collaboration with Daiichi Sankyo)
- 2025 Sales: ~$5.9 billion (AstraZeneca share included)
Executive Insight:
Enhertu highlights AstraZeneca’s success in antibody-drug conjugate platforms, enabling expansion across multiple HER2-expressing cancers.
Cardiovascular, Renal & Metabolism (CVRM)
Farxiga
- 2025 Sales: ~$5.5 billion
Farxiga remains a key growth driver across heart failure, chronic kidney disease, and diabetes indications.
Executive Insight:
CVRM provides durable growth through broad label expansion and increasing global uptake in chronic disease management.
Respiratory & Immunology
Fasenra
- 2025 Sales: ~$1.7 billion
Fasenra continues to strengthen AstraZeneca’s position in severe asthma and eosinophilic diseases.
Executive Insight:
Biologic respiratory therapies align with precision medicine trends and strengthen AstraZeneca’s specialty care portfolio.
Rare Disease Portfolio
Ultomiris
- 2025 Sales: ~$3.5 billion
Ultomiris drives growth in complement-mediated rare diseases with long-acting dosing advantages.
Executive Insight:
Rare diseases provide high-value, durable revenue streams supported by strong patient engagement and limited competition.
Portfolio Strategy and Executive Positioning
AstraZeneca’s portfolio reflects deliberate therapeutic concentration with global scalability. The company continues to prioritize:
- Platform-driven oncology expansion, particularly in ADCs and immuno-oncology
- Broad chronic disease leadership in CVRM
- Biologic innovation in respiratory and immunology
- Durable value creation in rare diseases
This balanced structure combines stable chronic disease revenues with high-growth oncology innovation.
Strategic Outlook
Looking ahead, AstraZeneca remains focused on:
- Expanding oncology platforms across tumor types and earlier lines of therapy
- Strengthening CVRM leadership through evidence-based label expansion
- Advancing next-generation biologics and rare disease therapies
- Sustaining disciplined capital allocation to support long-term innovation
With strong 2025 brand performance and a focused therapeutic strategy, AstraZeneca is positioned to maintain competitive leadership and deliver sustainable growth in the evolving global biopharma landscape.
By